Render Target: STATIC
Render Timestamp: 2025-03-14T10:33:28.763Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2024-09-20 06:23:31.147
Product last modified at: 2025-01-01T09:02:03.263Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Chemical Modulators
PDP - Template ID: *******c501c72

ML-323 #77681

    Product Information

    Product Usage Information

    ML-323 is supplied as a lyophilized powder. For a 15 mM stock, reconstitute 5 mg of powder in 0.87 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.

    Storage

    Store lyophilized at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

    Product Description

    Molecular Weight 384.5 g/mol
    Purity >98%
    Molecular Formula C23H24N6
    CAS 1571424-83-5
    Solubility Soluble in DMSO at 40 mg/mL or ethanol at 20 mg/mL.

    Background

    ML-323 is a small-molecule inhibitor of ubiquitin-specific protease 1 (USP1), a deubiquitinase associated with the DNA damage response. USP1 and the WD repeat-containing protein (WDR48, UAF1) form a deubiquitinase complex that removes ubiquitin from FANCD2, which is ubiquitinated in response to DNA damage. ML-323 is a potent (IC50 = 76 nM) and specific inhibitor of the USP1/UAF1 deubiquitinase complex (1). Dysregulation of USP1 is an aspect of several forms of cancer, making it a promising therapeutic target. ML-323 significantly repressed metastasis in a murine model of breast cancer (2) and decreased hepatocellular carcinoma cell proliferation (3). Elevated USP1 expression in some colorectal cancers is associated with short overall patient survival and advanced stages of cancers. USP1 knockdown resulted in growth arrest at G2/M and reduced anti-apoptotic protein expression; ML-323 sensitized colorectal cancer cells to DNA-targeting chemotherapeutics (4). ML-323 treatment of non-small cell lung cancer and osteosarcoma cells potentiates the cytotoxic effects of cisplatin (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.